secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0000950170-24-128266
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics licenses aficamten Japan rights to Bayer for €50M upfront, up to €580M milestones
--------------------------------------------------------------------------------

- Upfront payment of €50 million from Bayer; additional clinical/commercial launch milestones up to €90 million.
- Commercial milestone payments up to €490 million based on net sales thresholds.
- Tiered royalties on Japan net sales ranging from high-teens to low-thirty percent.
- Bayer responsible for development and commercialization at its own cost; Cytokinetics retains rights to ACACIA-HCM and CEDAR-HCM trials in Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024128266/0000950170-24-128266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017024128266/cytk-20241118.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-128266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer